Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531028 | 0.87 | HTT (0.45) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL1711445 | 0.87 | HTT (0.45) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL12220460 | 0.87 | HTT (0.45) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL1711441 | 0.87 | HTT (0.45) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL2532500 | 0.84 | LMNA (0.47) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL2532766 | 0.83 | OPRK1 (0.41) | OPRK1OPRM1 | |
| SCHEMBL2791040 | 0.81 | PIK3CA (0.40) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL2532492 | 0.77 | PIK3CA (0.57) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL1711450 | 0.76 | LMNA (0.39) | HTTLMNAPIK3CAMTORJAK3 | |
| SCHEMBL2533823 | 0.76 | HTT (0.46) | HTTLMNAPIK3CAMTORJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | HTT 3933/4885LMNA 4183/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.